Evidence map›Paper›PMID 40699361›Full record

ArticleWorld journal of urology2025

Oncological outcomes of open versus minimally invasive nephroureterectomy for locally advanced upper tract urothelial carcinoma.

Luca Afferi, Benjamin Pradere, Andrea Gallioli, Marco Moschini, Donato Cannoletta, Francesco Soria, Tristan Juvet, Aaron Potretzke, Hooman Djaladat, Eiji Kikuchi and 25 more

Abstract readMulticenter StudyComparative Study
PubMed Publisher
In one paragraph

Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Luca AfferiDepartment of Urology, Fundació Puigvert, Barcelona, Spain. luca.afferi@gmail.com.
Benjamin PradereDepartment of Urology, UROSUD, La Croix Du Sud Hospital, Quint- Fonsegrives, France.
Andrea GallioliDepartment of Urology, Fundació Puigvert, Barcelona, Spain.
Marco MoschiniDepartment of Urology, San Raffaele Hospital and Scientific Institute, Milan, Italy.
Donato CannolettaDepartment of Urology, San Raffaele Hospital and Scientific Institute, Milan, Italy.
Francesco SoriaDivision of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy.
Tristan JuvetDepartment of Urology, Lions Gate Hospital, North Vancouver, BC, Canada.
Aaron PotretzkeDepartment of Urology, Mayo Clinic, Rochester, MN, USA.
Hooman DjaladatDepartment of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Eiji KikuchiDepartment of Urology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Andrea MariDepartment of Urology, University of Florence, Careggi Hospital, Florence, Italy.
Zineddine KheneDepartment of Urology, University of Rennes, Rennes, France.
Kazutoshi FujitaDepartment of Urology, Kindai University Faculty of Medicine, Osaka, Japan.
Jay D RamanDepartment of Urology, Penn State Health, Hershey, PA, USA.
John P SfakianosDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
John L PfailDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Giovanni E CacciamaniKeck Medicine of USC, USC Institute of Urology, University of Southern California, Los Angeles, CA, USA.
Thomas van DoeverenDepartment of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
Joost L BoormansDepartment of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
Alessandro AntonelliDepartment of Urology, Azienda Ospedaliera Universitaria Integrata of Verona, University of Verona, Verona, Italy.
Marcus JamilVattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA.
Firas AbdollahVattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA.
Guillaume PloussardDepartment of Urology, UROSUD, La Croix Du Sud Hospital, Quint- Fonsegrives, France.
Axel HeidenreichDepartment of Urology, Uro-Oncology, Robot Assisted and Specialized Urologic Surgery, University Hospital Cologne, Cologne, Germany.
Constantin RiegerDepartment of Urology, Uro-Oncology, Robot Assisted and Specialized Urologic Surgery, University Hospital Cologne, Cologne, Germany.
Siamak DaneshmandDepartment of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Stephen A BoorjianDepartment of Urology, Mayo Clinic, Rochester, MN, USA.
Andreas SauerDepartment of Urology, Kantonsspital Aarau, Aarau, Switzerland.
Stephen WylerDepartment of Urology, Kantonsspital Aarau, Aarau, Switzerland.
Agostino MatteiDepartment of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.
Morgan RouprêtSorbonne University, AP-HP, Pitie- Salpetriere Hospital, GRC 5 Predictive Onco-Uro, Urology, PARIS, F-75013, France.
Michael RinkDepartment of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Shahrokh F ShariatHourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.
Alberto Breda *Department of Urology, Fundació Puigvert, Barcelona, Spain.
Nico C Grossmann *Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

INTRODUCTION &

objectivesIt is currently recommended to perform open radical nephroureterectomy (oRNU) with bladder cuff excision in patients with locally advanced (cT3-4 or cN1-2) upper tract urothelial carcinoma (laUTUC). We tested the hypothesis that bladder recurrence-free survival (BRFS), metastasis-free survival (MFS), cancer-specific survival (CSS) and overall survival (OS) are not influenced by the surgical approach in patients with laUTUC using a large multicenter series. MATERIAL &

methodsThis was a multicenter retrospective cohort study including 361 patients with preoperative cT3-4 cM0 or cN1-2 cM0 laUTUC treated with open or minimally invasive RNU from 1999 to 2019 at 21 academic centers in Europe, Asia, and the United States. Missing values of relevant baseline characteristics were estimated through multiple imputation of chained equations. Baseline patients' heterogeneity was balanced using a 1:1 propensity score matching estimated using logistic regression. Uni- and multivariable Cox regression analyses for bladder recurrence, metastasis, cancer-specific death and overall death were performed according to clinical and pathological characteristics. Kaplan Meier (KM) estimates and log-rank test were used to compare BRFS, MFS, CSS and OS according to clinical and pathological features.

resultsMedian follow-up was 28 months. After propensity score matching, two cohorts of 115 laUTUC patients each with similar baseline and preoperative tumor characteristics were obtained. In the matched cohort, pT ≥ 3 stage was found in 84 (73%) and 67 (58.3%) patients in the oRNU and miRNU groups, respectively. Positive lymph nodes were detected in 27 (23.5%) and 32 (27.8%) patients in the oRNU and miRNU groups, respectively. In the multivariable regression analysis, pT ≥ 3 and positive lymph nodes were associated with an increased risk of metastasis (HR 3.22, 95% CI 1.26-8.23, and HR 4.03, 95% CI 2.05-7.89, respectively). The surgical approach (oRNU vs. mi RNU) did not influence oncological outcomes as shown by uni- and multivariable analyses as well as Kaplan-Meier estimates, regardless of pT stage.

conclusionsThe oncological outcomes of laUTUC for cT3-4 cM0 or cN1-2 cM0 disease are comparable whether RNU is performed via an open or minimally invasive approach. Therefore, the decision to opt for oRNU or miRNU should be guided by the surgeon's expertise and the patient's comorbidities, rather than concerns over long-term oncological outcomes associated with either surgical technique.

Indexed as

Carcinoma, Transitional CellKidney NeoplasmsNephroureterectomyUreteral NeoplasmsAgedCohort StudiesFemaleHumansMaleMiddle AgedMinimally Invasive Surgical ProceduresNeoplasm StagingRetrospective StudiesSurvival RateTreatment OutcomeLocally advanced UtucMinimally-invasive nephroureterectomyOpen nephroureterectomyUpper tract urothelial cancerUtuc

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.